Sarepta Therapeutics | SRPT - Les Charges D'Exploitation





Les Charges D'Exploitation Changement Date
Acadia Pharmaceuticals USD 270.12M 2.55M 2026-06
Agios Pharmaceuticals USD 130.77M 10.77M 2026-03
Alnylam Pharmaceuticals USD 1.06B 160.97M 2026-06
Amgen USD 11.69B 6.9B 2026-06
BioCryst Pharmaceuticals USD 119.78M 673.63M 2026-06
Biogen USD 2.32B 663.6M 2026-09
BioMarin Pharmaceutical USD 6.32B 5.69B 2026-06
Capricor Therapeutics USD 29.16M 2.87M 2025-12
Daiichi Sankyo JPY 489.64B 21.08B 2026-06
Eli Lilly USD 10.52B 496M 2026-06
Gilead Sciences USD 3.95B 19.57B 2026-06
Incyte USD 973.64M 4.65B 2026-06
Insmed USD 526.79M 20.55M 2026-06
Ionis Pharmaceuticals USD 370.24M 6.24M 2026-06
Moderna USD 960M 817M 2026-06
Nektar Therapeutics USD 49.12M 8.22M 2026-03
Neurocrine Biosciences USD 739.1M 139.2M 2026-06
Novavax USD 126.2M 23.62M 2025-12
Pfizer USD 85.19B 4.91B 2026-06
PTC Therapeutics USD 211.54M 15.12M 2026-06
Regeneron Pharmaceuticals USD 31.71B 287.8M 2026-06
Roche Holding CHF 18.9B 2.12B 2026-06
Sangamo BioSciences USD 33.87M 12.89M 2024-06
Sanofi EUR 9.92B 607M 2026-06
Sarepta Therapeutics USD 387.96M 15.59M 2026-06
Tectonic Therapeutic USD 27.3M 5.78M 2026-03
Ultragenyx Pharmaceutical USD 289M 16M 2026-06
Vertex Pharmaceuticals USD 2.07B 217.1M 2026-06